Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Bimatoprost

FDA-approved product (solution/drops, ophthalmic), marketed as Bimatoprost, Durysta, Latisse and 2 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Bimatoprost
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Glaucoma
  • Hypotrichosis
  • Hypotrichosis simplex
  • Ocular hypertension
  • Open-angle glaucoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Prostaglandin analogues
FDA pharmacologic class
Prostaglandin Analog FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA40.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli35.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae24.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis54.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Bimatoprost in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Bimatoprost with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Retinal Ganglion Cell Neuroprotection Under Prostaglandin Analogues

    NCT07074782 · start 2026-05

    Registered record
    Registry ID
    NCT07074782
    Conditions
    Glaucoma
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Not yet recruiting
    Start
    2026-05
    Completion
    2026-06
    Enrolment
    1,500

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlaucoma
    InterventionNot recorded
    PhaseNot recorded
    Registry statusNot yet recruiting

  • Study of Corneal Biomechanics in Glaucoma Patients Using Brillouin Microscopy

    NCT06993597 · start 2025-09-01

    Registered record
    Registry ID
    NCT06993597
    Conditions
    Glaucoma
    Interventions
    Prostaglandin Analogue -Containing IOP-Lowering Therapy; Beta Blocker; Brillouin Microscopy
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2025-09-01
    Completion
    2027-06
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlaucoma
    InterventionProstaglandin Analogue -Containing IOP-Lowering Therapy; Beta Blocker; Brillouin Microscopy
    PhaseNot recorded
    Registry statusRecruiting

  • A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes

    NCT06267274 · start 2024-04-01

    Registered record
    Registry ID
    NCT06267274
    Conditions
    Open-angle Glaucoma; Ocular Hypertension
    Interventions
    Bimatoprost Ophthalmic Solution, 0.01%; LUMIGAN® (bimatoprost ophthalmic solution) 0.01%
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Unknown
    Start
    2024-04-01
    Completion
    2025-05-01
    Enrolment
    240

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpen-angle Glaucoma; Ocular Hypertension
    InterventionBimatoprost Ophthalmic Solution, 0.01%; LUMIGAN® (bimatoprost ophthalmic solution) 0.01%
    PhasePhase 1
    Registry statusUnknown

  • Aqueous Humor Dynamics of NCX 470 Ophthalmic Solution

    NCT05938699 · start 2023-12-12

    Registered record
    Registry ID
    NCT05938699
    Conditions
    Open Angle Glaucoma
    Interventions
    NCX 470; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2023-12-12
    Completion
    2025-03-17
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpen Angle Glaucoma
    InterventionNCX 470; Placebo
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • PSLT Compared to Prostaglandin Analogue Eye Drops

    NCT05241938 · start 2021-09-01

    Registered record
    Registry ID
    NCT05241938
    Conditions
    Open Angle Glaucoma; Ocular Hypertension
    Interventions
    PSLT; Prostaglandin analogue eye drops
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2021-09-01
    Completion
    2022-12-20
    Enrolment
    75

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpen Angle Glaucoma; Ocular Hypertension
    InterventionPSLT; Prostaglandin analogue eye drops
    PhaseNot applicable
    Registry statusUnknown

  • Efficacy and Safety Assessment of T4030 Eye Drops Versus Ganfort® UD in Ocular Hypertensive or Glaucomatous Patients.

    NCT04898387 · start 2021-03-26

    Registered record
    Registry ID
    NCT04898387
    Conditions
    Ocular Hypertension Glaucoma
    Interventions
    Bimatoprost Timolol (T4030); Bimatoprost Timolol (Ganfort)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2021-03-26
    Completion
    2023-05-30
    Enrolment
    554

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOcular Hypertension Glaucoma
    InterventionBimatoprost Timolol (T4030); Bimatoprost Timolol (Ganfort)
    PhasePhase 3
    Registry statusCompleted

  • A Phase 3b Study Evaluating the 24-Hour Intraocular Pressure Lowering Effect of Bimatoprost SR in Patients With Open-Angle Glaucoma or Ocular Hypertension

    NCT04285580 · start 2020-06-11

    Registered record
    Registry ID
    NCT04285580
    Conditions
    Open-Angle Glaucoma; Ocular Hypertension
    Interventions
    Bimatoprost SR; LUMIGAN
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2020-06-11
    Completion
    2022-05-14
    Enrolment
    37

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpen-Angle Glaucoma; Ocular Hypertension
    InterventionBimatoprost SR; LUMIGAN
    PhasePhase 3
    Registry statusCompleted

  • A Comparative Study of SPARC's SDP-133 Once Daily and Lumigan in Subjects With Open Angle Glaucoma or Ocular Hypertension

    NCT03927443 · start 2019-06-10

    Registered record
    Registry ID
    NCT03927443
    Conditions
    Open Angle Glaucoma; Ocular Hypertension
    Interventions
    SDP-133; Lumigan
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Withdrawn
    Start
    2019-06-10
    Completion
    2019-07-08
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpen Angle Glaucoma; Ocular Hypertension
    InterventionSDP-133; Lumigan
    PhasePhase 3
    Registry statusWithdrawn

  • Long-term Safety and Efficacy Extension Trial of Bimatoprost SR

    NCT03891446 · start 2019-03-27

    Registered record
    Registry ID
    NCT03891446
    Conditions
    Open-Angle Glaucoma; Ocular Hypertension
    Interventions
    Bimatoprost SR; Standard of Care
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2019-03-27
    Completion
    2026-06-19
    Enrolment
    455

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpen-Angle Glaucoma; Ocular Hypertension
    InterventionBimatoprost SR; Standard of Care
    PhasePhase 3
    Registry statusCompleted

  • Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension

    NCT03850782 · start 2019-02-28

    Registered record
    Registry ID
    NCT03850782
    Conditions
    Open-Angle Glaucoma; Ocular Hypertension
    Interventions
    Bimatoprost (SR)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2019-02-28
    Completion
    2025-08-08
    Enrolment
    515

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpen-Angle Glaucoma; Ocular Hypertension
    InterventionBimatoprost (SR)
    PhasePhase 3
    Registry statusCompleted

  • Topical Bimatoprost in the Treatment of Migraine

    NCT03419715 · start 2018-01-05

    Registered record
    Registry ID
    NCT03419715
    Conditions
    Migraine Disorders; Headache Disorders
    Interventions
    Bimatoprost Topical Solution; Control
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2018-01-05
    Completion
    2019-06-30
    Enrolment
    70

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine Disorders; Headache Disorders
    InterventionBimatoprost Topical Solution; Control
    PhasePhase 2
    Registry statusUnknown

  • Efficacy and Safety of COMBIGAN® in Korean Patients With Primary Open Angle Glaucoma (POAG) and Normal Tension Glaucoma (NTG)

    NCT02863705 · start 2016-07-05

    Registered record
    Registry ID
    NCT02863705
    Conditions
    Glaucoma, Open-Angle; Normal Tension Glaucoma
    Interventions
    brimonidine tartrate/timolol malate Ophthalmic Solution; bimatoprost ophthalmic solution 0.01%
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2016-07-05
    Completion
    2018-07-25
    Enrolment
    118

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlaucoma, Open-Angle; Normal Tension Glaucoma
    Interventionbrimonidine tartrate/timolol malate Ophthalmic Solution; bimatoprost ophthalmic solution 0.01%
    PhasePhase 4
    Registry statusCompleted

  • Safety, Tolerability, and Pharmacokinetics of Bimatoprost in Men With Androgenetic Alopecia (AGA)

    NCT02676310 · start 2016-03

    Registered record
    Registry ID
    NCT02676310
    Conditions
    Alopecia; Alopecia, Androgenetic; Baldness
    Interventions
    Bimatoprost
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2016-03
    Completion
    2017-03
    Enrolment
    53

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlopecia; Alopecia, Androgenetic; Baldness
    InterventionBimatoprost
    PhasePhase 1
    Registry statusTerminated

  • Safety of GANFORT® Ophthalmic Solution in Chinese Patients With Open-angle Glaucoma or Ocular Hypertension

    NCT02571712 · start 2015-11-10

    Registered record
    Registry ID
    NCT02571712
    Conditions
    Glaucoma, Open-Angle; Ocular Hypertension
    Interventions
    bimatoprost 0.03% plus timolol 0.5%
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2015-11-10
    Completion
    2018-06-21
    Enrolment
    750

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlaucoma, Open-Angle; Ocular Hypertension
    Interventionbimatoprost 0.03% plus timolol 0.5%
    PhasePhase 4
    Registry statusCompleted

  • SIMBRINZA® Suspension BID as an Adjunctive to Prostaglandin Analogue (PGA)

    NCT02419508 · start 2015-08-07

    Registered record
    Registry ID
    NCT02419508
    Conditions
    Open-Angle Glaucoma; Ocular Hypertension
    Interventions
    Brinzolamide 1%/brimonidine 0.2% tartrate ophthalmic suspension; Brinz/brim vehicle; Prostaglandin analogue
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2015-08-07
    Completion
    2018-02-27
    Enrolment
    290

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpen-Angle Glaucoma; Ocular Hypertension
    InterventionBrinzolamide 1%/brimonidine 0.2% tartrate ophthalmic suspension; Brinz/brim vehicle; Prostaglandin analogue
    PhasePhase 4
    Registry statusCompleted